A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus
A Randomized, Double-blind Study to Determine the Effect of GK Activator (2) on Efficacy (HbA1c), Safety, Tolerability and Pharmacokinetics in Patients With Type 2 Diabetes Mellitus
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Dimitrovgrad, Bulgaria, 6400
-
Pleven, Bulgaria, 5800
-
Ruse, Bulgaria, 7002
-
Sofia, Bulgaria, 1233
-
Sofia, Bulgaria, 1431
-
Sofia, Bulgaria, 1606
-
Sofia, Bulgaria, 1303
-
-
-
-
-
Zagreb, Croatia, 10000
-
-
-
-
-
Guatemala City, Guatemala, 01015
-
-
-
-
-
Budapest, Hungary, 1083
-
Budapest, Hungary, 1088
-
Gyor, Hungary, 9024
-
Kecskemet, Hungary, 6000
-
-
-
-
-
Chihuahua, Mexico, 31238
-
Cuernavaca, Mexico, 62250
-
Durango, Mexico, 34070
-
Mexico City, Mexico, 14050
-
Mexico City, Mexico, 11650
-
Mexico City, Mexico, 14610
-
Mexico-city, Mexico, 06700
-
-
-
-
-
Bialystok, Poland, 15-276
-
Gdansk, Poland, 80-757
-
Gorzow, Poland, 66-400
-
Krakow, Poland, 31-121
-
Wroclaw, Poland, 50-088
-
-
-
-
Arizona
-
Tucson, Arizona, United States, 85723
-
-
Arkansas
-
Pine Bluff, Arkansas, United States, 71603
-
-
California
-
Chula Vista, California, United States, 91911
-
Spring Valley, California, United States, 91978
-
West Hills, California, United States, 91307
-
-
Florida
-
Hollywood, Florida, United States, 33021
-
-
Georgia
-
Atlanta, Georgia, United States, 30308
-
-
New York
-
Binghamton, New York, United States, 13901
-
-
North Carolina
-
Fayetteville, North Carolina, United States, 28304
-
Statesville, North Carolina, United States, 28625
-
Winston-salem, North Carolina, United States, 27103
-
-
Ohio
-
Springdale, Ohio, United States, 45246
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73112
-
-
Oregon
-
Medford, Oregon, United States, 97504
-
-
Pennsylvania
-
Beaver, Pennsylvania, United States, 15009
-
Tipton, Pennsylvania, United States, 16684
-
-
South Carolina
-
Mount Pleasant, South Carolina, United States, 29464
-
-
Texas
-
Plano, Texas, United States, 75093
-
-
Washington
-
Renton, Washington, United States, 98055
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- adult patients 30-75 years of age;
- type 2 diabetes mellitus for >3 months before screening;
- treatment-naive, inadequately controlled diabetes despite diet and exercise, or inadequately controlled diabetes in patients on monotherapy or combination therapy (maximum of 2 oral anti-hyperglycemic medications).
Exclusion Criteria:
- type 1 diabetes mellitus;
- women who are pregnant, breast-feeding or not using adequate contraceptive methods.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 1
|
Escalating doses po bid
|
|
Experimental: 2
|
Escalating doses po bid
|
|
Experimental: 3
|
Escalating doses po bid
|
|
Experimental: 4
|
Escalating doses po bid
|
|
Placebo Comparator: 5
|
po bid
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
HbA1c mean change from baseline, compared to placebo.
Time Frame: Week 12
|
Week 12
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
AEs, laboratory parameters.
Time Frame: Throughout study
|
Throughout study
|
|
Additional parameters of glycemic and lipid control.
Time Frame: Week 12
|
Week 12
|
|
Pharmacokinetic and exposure-response relationship
Time Frame: Throughout study
|
Throughout study
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- BM18248
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.